SNORD50A

Summary

SNORD50A (small nucleolar RNA, C/D box 50A, HGNC:10200) is a gene on chromosome 6q14.3.

SNORD50A belongs to the C/D box class of small nucleolar RNAs (snoRNAs), which are thought to function as guide RNAs in the site-specific ribose methylation of preribosomal RNA (Kiss-Laszlo et al., 1996 [PubMed 8674114]).

Source: NCBI Gene 26799 — RefSeq curated summary.

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10200
Approved symbol	SNORD50A
Name	small nucleolar RNA, C/D box 50A
Location	6q14.3
Locus type	RNA, small nucleolar
Status	Approved
Aliases	U50
OMIM	613117
Entrez	26799
RNAcentral	URS00002524EE — snoRNA, 75 nt, 2 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 0

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

None — 0 exons

Expression profiles

Top tissues by expression

0 total, by Bgee expression score (0-100, higher = more expressed):

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 4)

• These findings establish snoRNA U50 as a reasonable candidate for the 6q tumor-suppressor gene in prostate cancer and likely in other types of cancers. (PMID:18202102)
• These results suggest that noncoding snoRNA U50 plays a role in the development and/or progression of breast cancer. (PMID:19683667)
• SNORD50A directly binds and inhibits K-Ras and is recurrently deleted in human cancer. (PMID:26595770)
• SNORD50A/B RNAs shape the composition of proteins proximal to KRAS, notably by inhibiting KRAS proximity to the SNARE vesicular transport proteins (PMID:31712554)

Cross-species orthologs

0 orthologs

Protein

Protein identifiers

Canonical reviewed UniProt: None (reviewed: )

All UniProt accessions (0):

RefSeq proteins (0): (*=MANE)

Domains & families (InterPro)

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 0 (showing top):

GO Biological Process (0):

GO Molecular Function (0):

GO Cellular Component (0):

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

0 interactions, top by confidence:

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

0 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000212406 (6:85678697 C>A,G,T), RS1001045088 (6:85678907 G>A,T), RS1001319671 (6:85676987 T>C), RS1001491918 (6:85678694 C>A,G,T), RS1001943933 (6:85678541 CAT>C), RS1002543775 (6:85679153 GGGCTGGCT>G,GGGCT,GGGCTGGCTGGCT,GGGCTGGCTGGCTGGCT), RS1003537719 (6:85678180 C>G), RS1004060283 (6:85678451 C>A), RS1004322392 (6:85677844 T>C), RS1005270968 (6:85678966 C>T), RS1005323446 (6:85678823 T>C), RS1005889338 (6:85677239 A>G), RS1007205629 (6:85678037 CA>C,CAA), RS1007753690 (6:85677755 T>C), RS1010857463 (6:85678685 C>A)

Disease associations

OMIM: gene MIM:613117 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

7 total (human), top 7 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression	1
potassium chromate(VI)	increases expression, affects cotreatment	1
epigallocatechin gallate	decreases expression, affects cotreatment, increases expression	1
Resveratrol	decreases expression, affects cotreatment	1
Acetaminophen	decreases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Aflatoxin B1	decreases methylation	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.